GILD

Gilead Sciences: The Market Is Underestimating Its Growth Runway

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership